Oak vs REMEVi
Two GLP-1 desks, one scoreboard. We put Oak and REMEVi head-to-head on the published Brief Score — the same six factors, scored the same way.
REMEVi
The verdict
REMEVi takes this head-to-head.
REMEVi scores 87 to 43 on our six-factor Brief Score — REMEVi is the first bilingual (English and Spanish) GLP-1 telehealth clinic — care delivered by clinicians trained in both languages, never auto-translated.
That doesn't make Oak a bad call — it's best for readers weighing oak specifically who want to know what it does and does not publish before handing over 29 questions' worth of medical history — not readers trying to compare a price today. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Oak | REMEVi | |
|---|---|---|
| Brief Score | 43/100 (C) | 87/100 (B+) |
| Semaglutide | $250/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $200/mo that morning | $219/mo (all doses, compounded) |
| Tirzepatide | $300/mo (one flat rate at every dose), read on its order form the afternoon of 15 August; it showed $250/mo that morning | $319/mo (all doses, compounded) |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Newnew to the tracker, no prior reading |
Oak: Re-read twice on 15 August 2026 with a real browser and no form input, and the figures MOVED BETWEEN THE TWO READS. In the morning its order form showed $200/mo for compounded semaglutide and $250 for tirzepatide; that afternoon, same URL, same entry path, browser storage cleared as a control, it showed $250 and $300 with the strike-throughs gone and every brand line $100 higher. What is stable is WHERE the price is: on the first screen of its order form, before a single question. The tracker previously carried no figure because the ladder was believed to be behind a 29-question intake — it is not, it is in front of it. What remains true is that Oak advertises nine different "starting" prices at once — $119, $133, $160, $167, $180, $185, $190, $199 and $250 — attaches a term to none, and that its headline "$133 / $199" is the three-month prepay under code OAKSAVE200, billed upfront.
REMEVi: New to the tracker on 1 August 2026, and read on the provider's own site rather than taken on trust: we checked https://remevihealth.com/pricing on 2026-08-01 and this row reflects what that page says. The line we publish is $219/mo (all doses, compounded). There is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.